Accretion Pharmaceuticals Limited (NSE:ACCPL)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Manufacturing and Sale of Pharmaceutical Products	573.76M	133.53M	295.32M	225.84M
Manufacturing and Sale of Pharmaceutical Products Growth	329.70%	-54.79%	30.76%	-
Total	573.76M	133.53M	295.32M	225.84M
Total Growth	329.70%	-54.79%	30.76%	-

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
India	526.12M	123.81M	293.33M	222.92M
India Growth	324.95%	-57.79%	31.58%	-
outside India	47.64M	9.72M	-	-
outside India Growth	390.31%	-	-	-
Export	-	-	517.00K	-
Total	573.76M	133.53M	293.84M	222.92M
Total Growth	329.70%	-54.56%	31.82%	-

Source: S&P Global Market Intelligence.